News

Rob Quinn To Join BenevolentAI As Chief Financial Officer in January 2021

BenevolentAI was founded with the belief that innovative thinking united with purposeful technology can lead to innovation that will fundamentally change patients’ lives for the better.  As we scale our bold and audacious mission, we require equally specialist expertise to guide our growth and financial direction.

To help us meet this need, we are thrilled to be welcoming Rob Quinn to the BenevolentAI team as our new Chief Finance Officer from January 2021.  He will take overall responsibility for the Finance Organisation, with a focus on investor relations, fundraising, revenue opportunities and realising our long term growth plans.

Rob brings with him a wealth of scientific and financial experience, having served at GSK as Area Finance Director for Africa & Developing Countries, and as CFO of Silence Therapeutics plc, where he led their listing on Nasdaq. He obtained a PhD in Biochemistry from the University of Manchester and qualified as a Chartered Accountant at Deloitte, where he spent time working in corporate finance advisory within the life sciences sector.

"I am excited to be joining BenevolentAI as Chief Financial Officer” Rob commented, “Benevolent is a business with huge potential and big ambitions to transform the lives of patients, and I look forward to playing my part". 

Under Rob’s financial guidance, we will confidently continue to move towards greater levels of innovation by investing in building richer and better technology that will help uncover vital new treatments. 


More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021